von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
复制标题
DOI：
10.1055/s-0040-1715440
复制
发表时间：
2021-01
影响因子：
6.7
通讯作者：
McCabe DJH
中科院分区：
文献类型：
--
作者：
Murphy SJX;Lim ST;Hickey F;Kinsella JA;Smith DR;Tierney S;Egan B;Feeley TM;Murphy SM;Collins DR;Coughlan T;O'Neill D;Harbison JA;Madhavan P;O'Neill SM;Colgan MP;O'Donnell JS;O'Sullivan JM;Hamilton G;McCabe DJH
血管性血友病因子抗原（VWF：Ag）、血管性血友病因子前肽（VWFpp）、VWFpp/VWF：Ag比、ADAMTS 13活性和颈动脉狭窄中微栓塞信号（MES）状态之间的关系尚不清楚。这项前瞻性、多中心研究同时评估了无症状与症状性≥50-99%颈动脉狭窄患者的血浆VWF：Ag、VWFpp水平和ADAMTS 13活性及其与MES状态的关系。大脑中动脉的1小时经颅多普勒超声将患者分为MES+ve或MES-ve。将34例无症状患者的数据与TIA/缺血性卒中后“早期"（≤4周）的43例有症状患者和”晚期"（≥3个月）的37例患者的数据进行比较。总体而言，早期有症状患者的VWF：Ag水平高于无症状患者（P=0.049），VWFpp/VWF：Ag比值低于无症状患者（P=0.006），早期有症状与无症状MES-ve亚组（P≤0.02）。VWFpp表达或ADAMTS 13活性无组间差异（P≥0.05）。有症状的TIA/卒中患者从早期到晚期随访，VWF：Ag水平和ADAMTS 13活性降低（P≤0.048），VWFpp/VWF：Ag比值升高（P=0.03）。尽管O型血的症状性和无症状性患者的比例无差异，但对早期症状性和无症状性患者的联合分析显示，O型血患者的中位VWF：Ag水平低于无O型血患者（9.59与12.32 µg/mL，p 0.035）。VWF：Ag表达是内皮+/−血小板活化的标志物，在近期有症状与无症状颈动脉狭窄患者（包括MES-ve患者）中增强，并在动脉粥样硬化性TIA/缺血性卒中后随时间推移随ADAMTS 13活性降低。
The relationship between von Willebrand factor antigen (VWF:Ag), von Willebrand factor propeptide (VWFpp), VWFpp/VWF:Ag ratio, ADAMTS13 activity and micro-embolic signal (MES) status in carotid stenosis is unknown. This prospective, multi-centre study simultaneously assessed plasma VWF:Ag, VWFpp levels and ADAMTS13 activity and their relationship with MES status in asymptomatic versus symptomatic ≥50–99% carotid stenosis patients. One-hour transcranial Doppler ultrasound of the middle cerebral arteries classified patients as MES+ve or MES-ve. Data from 34 asymptomatic patients were compared with 43 symptomatic patients in the ‘early phase’ (≤4 weeks) and 37 patients in the ‘late phase’ (≥3 months) after TIA/ischaemic stroke. VWF:Ag levels were higher (P=0.049) and VWFpp/VWF:Ag ratios were lower (P=0.006) in early symptomatic than asymptomatic patients overall, and in early symptomatic vs. asymptomatic MES-ve subgroups (P≤0.02). There were no inter-group differences in VWFpp expression or ADAMTS13 activity (P≥0.05). VWF:Ag levels and ADAMTS13 activity (P≤0.048) decreased and VWFpp/VWF:Ag ratios increased (P=0.03) in symptomatic patients followed up from the early to late phases after TIA/stroke. Although there were no differences in the proportions of symptomatic and asymptomatic patients with blood group O, a combined analysis of early symptomatic and asymptomatic patients revealed lower median VWF:Ag levels in patients with blood group O versus those without blood group O (9.59 vs. 12.32 µg/mL, p 0.035). VWF:Ag expression, a marker of endothelial +/− platelet activation, is enhanced in recently symptomatic versus asymptomatic carotid stenosis patients, including in MES-ve patients, and decreases with ADAMTS13 activity over time following atherosclerotic TIA/ischaemic stroke.
登录
查看更多内容
影响因子：
10.4
作者：
Kinsella, J. A.;Tobin, W. O.;McCabe, D. J. H.
通讯作者：
McCabe, D. J. H.
影响因子：
1.1
作者：
Gogia S;Neelamegham S
通讯作者：
Neelamegham S
影响因子：
8.3
作者：
De Meyer SF;Stoll G;Wagner DD;Kleinschnitz C
通讯作者：
Kleinschnitz C
影响因子：
5
作者：
Alpoim, Patricia N.;Gomes, Karina B.;Dusse, Luci M.
通讯作者：
Dusse, Luci M.
影响因子：
9.9
作者：
Bustamante, Alejandro;Ning, MingMing;Montaner, Joan
通讯作者：
Montaner, Joan